Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.

Molecular cell - 7 Oct 2021

Liu Zhiwei, Liu Yingluo, Qian Lili, Jiang Shangwen, Gai Xiameng, Ye Shu, Chen Yuehong, Wang Xiaomin, Zhai Linhui, Xu Jun, Pu Congying, Li Jing, He Fuchu, Huang Min, Tan Minjia

Abstract excerpt

KRAS mutant cancer, characterized by the activation of a plethora of phosphorylation signaling pathways, remains a major challenge for cancer therapy. Despite recent advancements, a comprehensive profile of the proteome and phosphoproteome is lacking. This study provides a proteomic and phosphoproteomic landscape of 43 KRAS mutant cancer cell lines across different tissue origins. By integrating transcriptomics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Guanine Nucleotide Exchange Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone-Lysine N-Methyltransferase

Share to Mass Spectrometry

Share to Mitogen-Activated Protein Kinases

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Proteome

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 34375582
DOI: 10.1016/j.molcel.2021.07.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.PMID 34375582Read ↗

ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising.Semantic proximity Read ↗

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.Semantic proximity Read ↗

Integrated multi-omics characterization of KRAS mutant colorectal cancer.Semantic proximity Read ↗

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomasSemantic proximity Read ↗

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.Semantic proximity Read ↗

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

Pan-cancer proteogenomic investigations identify post-transcriptional kinase targetsSemantic proximity Read ↗

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Developing SHP2-based combination therapy for KRAS-amplified cancer.Semantic proximity Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of SotorasibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.